|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Xie E, Lin M, Sun Z, Jin Y, Zhang S, Huang
L, Sun R, Wang F and Pan S: Serum miR-27a is a biomarker for the
prognosis of non-small cell lung cancer patients receiving
chemotherapy. Transl Cancer Res. 10:3458–3469. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Garon EB, Hellmann MD, Rizvi NA, Carcereny
E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L,
et al: Five-year overall survival for patients with advanced
non-small-cell lung cancer treated with pembrolizumab: Results from
the phase I KEYNOTE-001 Study. J Clin Oncol. 37:2518–2527.
2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Albano D, Bilfinger T and Nemesure B: 1-,
3-, and 5-year survival among early-stage lung cancer patients
treated with lobectomy vs SBRT. Lung Cancer (Auckl). 9:65–71.
2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Lutfi W, Schuchert MJ, Dhupar R, Sarkaria
I, Christie NA, Yang CJ, Deng JZ, Luketich JD and Okusanya OT:
Sublobar resection is associated with decreased survival for
patients with early stage large-cell neuroendocrine carcinoma of
the lung. Interact Cardiovasc Thorac Surg. 29:517–524.
2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Luo B, Mao G, Ma H and Chen S: The role of
seven autoantibodies in lung cancer diagnosis. J Thorac Dis.
13:3660–3668. 2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhang X, Liu M, Zhang X, Wang Y and Dai L:
Autoantibodies to tumor-associated antigens in lung cancer
diagnosis. Adv Clin Chem. 103:1–45. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Trudgen K, Khattar NH, Bensadoun E, Arnold
S, Stromberg AJ and Hirschowitz EA: Autoantibody profiling for lung
cancer screening longitudinal retrospective analysis of CT
screening cohorts. PLoS One. 9(e87947)2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sullivan FM, Farmer E, Mair FS, Treweek S,
Kendrick D, Jackson C, Robertson C, Briggs A, McCowan C, Bedford L,
et al: Detection in blood of autoantibodies to tumour antigens as a
case-finding method in lung cancer using the
EarlyCDT®-Lung Test (ECLS): Study protocol for a
randomized controlled trial. BMC Cancer. 17(187)2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chen SS, Li K, Wu J, Peng ZY, Wang ZD,
Wang JC, Xu CW, Zhu CL, Li BC, Ren H, et al: Stem signatures
associated antibodies yield early diagnosis and precise prognosis
predication of patients with non-small cell lung cancer. J Cancer
Res Clin Oncol. 147:223–233. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Du Q, Yu R, Wang H, Yan D, Yuan Q, Ma Y,
Slamon D, Hou D, Wang H and Wang Q: Significance of
tumor-associated autoantibodies in the early diagnosis of lung
cancer. Clin Respir J. 12:2020–2028. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ren S, Zhang S, Jiang T, He Y, Ma Z, Cai
H, Xu X, Li Y, Cai W, Zhou J, et al: Early detection of lung cancer
by using an autoantibody panel in Chinese population.
Oncoimmunology. 7(e1384108)2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Saini J and Sharma PK: Clinical,
prognostic and therapeutic significance of heat shock proteins in
cancer. Curr Drug Targets. 19:1478–1490. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wang X, Song X, Zhuo W, Fu Y, Shi H, Liang
Y, Tong M, Chang G and Luo Y: The regulatory mechanism of
Hsp90alpha secretion and its function in tumor malignancy. Proc
Natl Acad Sci U S A. 106:21288–21293. 2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
WHO Classification of Tumours Editorial
Board. WHO Classification of Tumours. Thoracic Tumours. 5th
edition. IARC Press, Lyon, 2021.
|
|
16
|
Balata H, Fong KM, Hendriks LE, Lam ṀS,
Ostroff JS, Peled N, Wu N and Aggarwal C: Prevention and early
detection for NSCLC: Advances in thoracic oncology 2018. J Thorac
Oncol. 14:1513–1527. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhang R, Ma L, Li W, Zhou S and Xu S:
Diagnostic value of multiple tumor-associated autoantibodies in
lung cancer. Onco Targets Ther. 12:457–469. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Stein Y, Rotter V and Aloni-Grinstein R:
Gain-of-function mutant p53: All the roads lead to tumorigenesis.
Int J Mol Sci. 20(6197)2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Lacroix M, Riscal R, Arena G, Linares LK
and Le Cam L: Metabolic functions of the tumor suppressor p53:
Implications in normal physiology, metabolic disorders, and cancer.
Mol Metab. 33:2–22. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Nanami T, Hoshino I, Shiratori F, Yajima
S, Oshima Y, Suzuki T, Ito M, Hiwasa T, Kuwajima A and Shimada H:
Presence of serum RalA and serum p53 autoantibodies in 1833
patients with various types of cancers. Int J Clin Oncol. 27:72–76.
2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang T, Li Y, Zhu R, Song P, Wei Y, Liang
T and Xu G: Transcription factor p53 suppresses tumor growth by
prompting pyroptosis in non-small-cell lung cancer. Oxid Med Cell
Longev. 2019(8746895)2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Mu Y, Xie F and Sun T: Clinical value of
seven autoantibodies combined detection in the diagnosis of lung
cancer. J Clin Lab Anal. 34(e23349)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Meng X, Sun X, Liu Z and He Y: A novel era
of cancer/testis antigen in cancer immunotherapy. Int
Immunopharmacol. 98(107889)2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Li S, Ma Y, Xiong Y, Zhang P, Wang X, Wang
Y and Yang Y: Five tumor-associated autoantibodies expression
levels in serum predict lung cancer and associate with poor
outcome. Transl Cancer Res. 8:1364–1373. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Huang H, Luo W, Ni Y, Sun S, Wang C and
Zhang L: The diagnostic efficiency of seven autoantibodies in lung
cancer. Eur J Cancer Prev. 29:315–320. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Wang Y, Jiao Y, Ding CM and Sun WZ: The
role of autoantibody detection in the diagnosis and staging of lung
cancer. Ann Transl Med. 9(1673)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Novak D, Hüser L, Elton JJ, Umansky V,
Altevogt P and Utikal J: SOX2 in development and cancer biology.
Semin Cancer Biol. 67:74–82. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chaudhary S, Islam Z, Mishra V, Rawat S,
Ashraf GM and Kolatkar PR: Sox2: A regulatory factor in
tumorigenesis and metastasis. Curr Protein Pept Sci. 20:495–504.
2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Mollaoglu G, Jones A, Wait SJ,
Mukhopadhyay A, Jeong S, Arya R, Camolotto SA, Mosbruger TL,
Stubben CJ, Conley CJ, et al: The lineage-defining transcription
factors SOX2 and NKX2-1 determine lung cancer cell fate and shape
the tumor immune microenvironment. Immunity. 49:764–779.
2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Schaal CM, Bora-Singhal N, Kumar DM and
Chellappan S: Regulation of Sox2 and stemness by nicotine and
electronic-cigarettes in non-small cell lung cancer. Mol Cancer.
17(149)2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Fang Y and Shen X: Ubiquitin
carboxyl-terminal hydrolases: Involvement in cancer progression and
clinical implications. Cancer Metastasis Rev. 36:669–682.
2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chen P, Lu W and Chen T: Seven
tumor-associated autoantibodies as a serum biomarker for primary
screening of early-stage non-small cell lung cancer. J Clin Lab
Anal. 35(e24020)2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Han Y, Zhang Y, Cui L, Li Z, Feng H, Zhang
Y, Sun D and Ren L: Plasma heat shock protein 90alpha as a
biomarker for the diagnosis of liver cancer: In patients with
different clinicopathologic characteristics. World J Surg Oncol.
19(228)2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wang Y, Barghi SM, Yang Y and
Akhavan-Sigari R: Value of HSP90α in lung cancer diagnosis and
recurrence prediction: A cohort study. Oncol Res Treat. 44:583–589.
2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kasanga M, Liu L, Xue L and Song X: Plasma
heat shock protein 90-alpha have an advantage in diagnosis of
colorectal cancer at early stage. Biomark Med. 12:881–890.
2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ichikawa T, Shanab O, Nakahata S,
Shimosaki S, Manachai N, Ono M, Iha H, Shimoda K and Morishita K:
Novel PRMT5-mediated arginine methylations of HSP90A are essential
for maintenance of HSP90A function in NDRG2low ATL and various
cancer cells. Biochim Biophys Acta Mol Cell Res.
1867(118615)2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhao Q, Miao C, Lu Q, Wu W, He Y, Wu S,
Liu H and Lian C: Clinical significance of monitoring circulating
free DNA and plasma heat shock protein 90alpha in patients with
esophageal squamous cell carcinoma. Cancer Manag Res. 13:2223–2234.
2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Chen C, Wang YS, Zhang ET, Li GA, Liu WY,
Li Y and Jin YH: (20S) Ginsenoside Rh2 exerts its anti-tumor effect
by disrupting the HSP90A-Cdc37 system in human liver cancer cells.
Int J Mol Sci. 22(13170)2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Song KH, Oh SJ, Kim S, Cho H, Lee HJ, Song
JS, Chung JY, Cho E, Lee J, Jeon S, et al: HSP90A inhibition
promotes anti-tumor immunity by reversing multi-modal resistance
and stem-like property of immune-refractory tumors. Nat Commun.
11(562)2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Fu Y, Xu X, Huang D, Cui D, Liu L, Liu J,
He Z, Liu J, Zheng S and Luo Y: Plasma heat shock protein 90alpha
as a biomarker for the diagnosis of liver cancer: An official,
large-scale, and multicenter clinical trial. EBioMedicine.
24:56–63. 2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Zhong B, Shen J, Zhang C, Zhou G, Yu Y,
Qin E, Tang J, Wu D and Liang X: Plasma heat shock protein 90
alpha: A valuable predictor of early chemotherapy effectiveness in
advanced non-small-cell lung cancer. Med Sci Monit.
27(e924778)2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ojha R, Nepali K, Chen CH, Chuang KH, Wu
TY, Lin TE, Hsu KC, Chao MW, Lai MJ, Lin MH, et al: Isoindoline
scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the
growth of lung cancer in vitro and in vivo. Eur J Med Chem.
190(112086)2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Pan J, Jiang F, Zhou J, Wu D, Sheng Z and
Li M: HSP90: A novel target gene of miRNA-628-3p in A549 cells.
Biomed Res Int. 2018(4149707)2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Shi Y, Liu X, Lou J, Han X, Zhang L, Wang
Q, Li B, Dong M and Zhang Y: Plasma levels of heat shock protein 90
alpha associated with lung cancer development and treatment
responses. Clin Cancer Res. 20:6016–6022. 2014.PubMed/NCBI View Article : Google Scholar
|
